Stockreport

Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF small molecules for diseases with significant unmet medical need, announced today the appointment of Michael D. Harvey , Ph.D. as Chief Development Officer. Dr. Harvey i [Read more]